TABLE 1.

Percentage of overall total cost for each agent, and comparison between Quadrant 1 (low cost, good outcome) and the other quadrants

Agent	Number of items prescribed	Overall (% of total cost per practice)		Relationship to Quadrant 1 (low cost, good outcome)	p‐value
		Median	IQR
Overall
Insulin	453,839	38.4	32.4–44.1
DPP‐IV inhibitors	382,068	20.5	15.8–24.6
SGLT2 inhibitor	314,522	11.9	9.0–17.1
GLP‐1 agonist	83,199	11.9	9.5–15.5
Biguanide	1,366,399	10.3	8.83–12.0
Sulphonylurea	495,417	2.41	1.7–3.13
Thiazolidinediones	49,100	0.3	0.16–0.65
	Quadrant 1 Low Cost, meeting metabolic target
Insulin		41.2	37.2–45.6	NA
DPP‐IV inhibitors		20.6	16.9–23.9	NA
SGLT2 inhibitor		9.7	7.6–13.5	NA
GLP‐1 agonist		11.3	7.8–14.1	NA
Biguanide		11.4	9.8–13.0	NA
Sulphonylurea		3.0	2.3–3.7	NA
Thiazolidinediones		0.3	0.2–0.7	NA
	Quadrant 2 High Cost, meeting metabolic target
Insulin		33.3	28.4–38.1	$\downarrow$	<0.001
DPP‐IV inhibitors		21.4	16.4–25.9		0.38
SGLT2 inhibitor		16	11.5–22.7	$\uparrow$	<0.001
GLP‐1 agonist		13.2	10.6–16.6	$\uparrow$	0.002
Biguanide		9.24	7.9–10.4	$\downarrow$	<0.001
Sulphonylurea		1.7	1.21–2.43	$\downarrow$	<0.001
Thiazolidinediones		0.4	0.2–0.7		0.42
	Quadrant 3 Low Cost, not meeting metabolic target
Insulin		43.2	39.0–47.6		0.13
DPP‐IV inhibitors		19.0	14.4–22.8	$\downarrow$	0.05
SGLT2 inhibitor		9.9	7.7–12.6		0.92
GLP‐1 agonist		11.3	8.7–15.5		0.40
Biguanide		11.7	10.3–12.7		0.62
Sulphonylurea		3.0	2.4–3.7		0.60
Thiazolidinediones		0.4	0.2–0.7		0.07
	Quadrant 4 High cost, not meeting metabolic target
Insulin		35.8	28.7–40.4	$\downarrow$	<0.001
DPP‐IV inhibitors		21.0	15.8–25.4		0.94
SGLT2 inhibitor		14.1	10.9–23.1	$\uparrow$	<0.001
GLP‐1 agonist		11.5	8.1–15.3		0.49
Biguanide		9.26	6.98–10.6	$\downarrow$	<0.001
Sulphonylurea		2.1	1.4–2.6	$\downarrow$	<0.001
Thiazolidinediones		0.3	0.1–0.5		0.29